B2M and renal cell carcinoma: Moreover, for the patients with advanced RCC treated with Avelumab (PD‐L1 antibody) from the phase 3 JAVELIN Renal 101 trial (n = 354; NCT02684006),[15] higher expression of B2M also predicted better progression‐free survival (PFS) (Figure 4H).